Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities research analysts at HC Wainwright raised their Q3 2027 EPS estimates for shares of Immunovant in a report released on Tuesday, November 10th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.77) for the quarter, up from their prior forecast of ($0.78). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Immunovant's current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Immunovant's FY2027 earnings at ($2.81) EPS, FY2028 earnings at ($3.46) EPS and FY2029 earnings at ($0.84) EPS.
IMVT has been the topic of several other research reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Immunovant in a research note on Tuesday, August 25th. Sanford C. Bernstein raised Immunovant to a "hold" rating in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Immunovant in a research report on Friday, October 2nd. Wells Fargo & Company raised their price target on Immunovant from $45.00 to $47.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 10th. Finally, Citigroup reiterated a "positive" rating on shares of Immunovant in a report on Thursday, September 24th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $44.60.
Get Our Latest Report on IMVT
Immunovant Price Performance
Shares of NASDAQ IMVT opened at $33.21 on Wednesday. The company's fifty day moving average is $32.39 and its 200-day moving average is $32.40. Immunovant has a twelve month low of $21.86 and a twelve month high of $45.42.
Immunovant (NASDAQ:IMVT - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.27. During the same quarter last year, the firm posted ($0.73) EPS.
Insider Buying and Selling at Immunovant
In other Immunovant news, CTO Jay Stout sold 3,809 shares of the business's stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $32.06, for a total value of $122,116.54. Following the sale, the chief technology officer owned 201,532 shares in the company, valued at approximately $6,461,115.92. The trade was a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Tiago Girão sold 6,606 shares of the company's stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $28.50, for a total value of $188,271.00. Following the transaction, the chief financial officer directly owned 234,192 shares of the company's stock, valued at approximately $6,674,472. This trade represents a 2.74% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 27,430 shares of company stock valued at $895,852 in the last 90 days. 1.90% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Immunovant in the 2nd quarter valued at $276,680,000. Two Seas Capital LP increased its position in Immunovant by 46.5% during the 3rd quarter. Two Seas Capital LP now owns 4,612,692 shares of the company's stock worth $155,817,000 after buying an additional 1,464,187 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of Immunovant by 8.0% during the first quarter. ADAR1 Capital Management LLC now owns 2,679,010 shares of the company's stock worth $66,547,000 after buying an additional 198,042 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Immunovant during the second quarter worth $45,521,000. Finally, Aberdeen Group plc lifted its holdings in shares of Immunovant by 2.6% during the third quarter. Aberdeen Group plc now owns 879,334 shares of the company's stock worth $29,704,000 after buying an additional 22,304 shares in the last quarter. 47.08% of the stock is owned by institutional investors and hedge funds.
About Immunovant
(
Get Free Report)
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company's investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves' disease and other autoimmune disorders.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunovant, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.
While Immunovant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.